South Korea CDC Cuts Plan To Vaccinate Children Against Hepatitis B
This article was originally published in PharmAsia News
The South Korean administration has reneged on a promise to provide 90 percent support for a national vaccination program to protect children against hepatitis B
You may also be interested in...
Merck & Co.'s vericiguat, an sGC stimulator, was approved for heart failure but it enters a competitive space with a narrow indication.
A top executive at the Swedish company spoke with Medtech Insight about how the mobility and data reliability of 5G cellular technology will change how medtech manufacturers design their products.
Roche's Actemra is a major player in this space, but Humanigen is looking to take it on directly.